Positive data in sativex® phase IIb trial: Support advancing into phase III development in cancer pain
Revista de la Sociedad Española del Dolor · 2010
DOI: 10.1016/j.resed.2010.02.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista de la Sociedad Española del Dolor, 2010. Verfasst von G. Guy und 4 weiteren Autor:innen. Die Arbeit nennt 1 Literaturangaben.
Abstract (Originalsprache)
Porton Down, UK; 23 March 2010: GW Pharmaceuticals plc (AIM: GWP) today announced preliminary results of a Phase IIb dose-ranging trial evaluating the efficacy and safety of Sativex in the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. This trial was performed in conjunction with GW’s licensing partner for Sativex in the United States—Otsuka Pharmaceutical Co. Ltd. In Europe, Sativex is in the advanced stages of a regulatory submission in the UK and Spain as a treatment for multiple sclerosis spasticity with approvals expected in Q2 2010. In the US, cancer pain represents the initial target indication for Sativex. Key points:
Zitieren
APA
Guy, G., Gover, J., Rogerson, M., Atwell, B., & Dineen, J. (2010). Positive data in sativex® phase IIb trial: Support advancing into phase III development in cancer pain. Revista de la Sociedad Española del Dolor. https://doi.org/10.1016/j.resed.2010.02.002
Vancouver
Guy G, Gover J, Rogerson M, Atwell B, Dineen J. Positive data in sativex® phase IIb trial: Support advancing into phase III development in cancer pain. Revista de la Sociedad Española del Dolor. 2010. doi:10.1016/j.resed.2010.02.002
BibTeX
@article{Guy2010,
author = {Guy, G. and Gover, J. and Rogerson, M. and Atwell, B. and Dineen, J.},
title = {Positive data in sativex® phase IIb trial: Support advancing into phase III development in cancer pain},
journal = {Revista de la Sociedad Española del Dolor},
year = {2010},
doi = {10.1016/j.resed.2010.02.002}
}
EUVIMED